ReviewReproductive biology and endocrinology : RB&E2023
Stop GnRH-agonist/GnRH-antagonist protocol: a different insight on ovarian stimulation for IVF.
Review in Reproductive biology and endocrinology : RB&E, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A novel approach to treating Endometriosis-Related Repeated IVF failures- insights from single case report.Reproductive biology and endocrinology : RB&E · 2026Article
- Stop gonadotropin-releasing hormone-agonist protocol not superior to antagonist protocol on the outcomes of assisted reproductive techniques in poor responders: A randomized clinical trial.International journal of reproductive biomedicine · 2026Article
- Efficacy of Stop GnRH-Agonist/Antagonist versus GnRH-Antagonist Protocols inInternational journal of fertility & sterility · 2026Article
- First clinical pregnancy and delivery achieved after using a new 3D imaging technology for sperm selection: a case report.Frontiers in reproductive health · 2025Article
- Development and validation of a nomogram for failure to collect oocytes in POSEIDON Groups 3 and 4 undergoing IVF/ICSI treatment.Scientific reports · 2024Article
- LH level on trigger day, number of follicles ≥16 mm but <18 mm, and number of retrieved oocytes are independent risk factors for polyspermy in gonadotropin-releasing hormone antagonist protocol.Frontiers in endocrinology · 2024Article
- Comparison of Cumulative Live Birth Rates between Flexible and Conventional Progestin-Primed Ovarian Stimulation Protocol in Poor Ovarian Response Patients According to POSEIDON Criteria: A Cohort Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian stimulation (OS) is one of the key factors in the success of in vitro fertilization-embryo transfer (IVF-ET), by enabling the recruitment of numerous healthy fertilizable oocytes and, thereby, multiple embryos. The Stop GnRH-agonist/GnRH-antagonist (GnRH-ag/GnRH-ant), which offers all the advantages of using long suppressive GnRH-ag, with GnRH-ant, is in my opinion a valuable addition to the armamentarium of OS protocols. It allows cycle programming, better follicular synchronization and offers successful outcome in a variety of challenging cases such as poor responders, Poseidon group 4 poor prognosis patients, those with elevated peak progesterone (P) serum levels, poor embryo quality or repeated IVF failures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.